Therapeutic and Diagnostic Pipelines
Listed below are the current Oncology, Infectious Disease & Transplant, Autoimmune, Neurology & Fibrosis, Platform & Reagent, and Diagnostic projects currently in the works for QIMR Berghofer. For a printable pdf of the following please click the following button.
Therapeutic Pipeline
Oncology
Completed
Started
Target
Undisclosed
Modality
mAb
Indication
Undisclosed
Pre-Clinical
Discovery
Hit Identification
Lead Optimisation
IND Enabling
Clinical
Phase I
Phase II
Partner
Partner
Target
CMV
Modality
CTL Platform
Indication
Glioblastoma
Pre-Clinical
Discovery
Hit Identification
Lead Optimisation
IND Enabling
Clinical
Phase I
Phase II
Target
EBV
Modality
CTL Platform
Indication
Head & Neck
Pre-Clinical
Discovery
Hit Identification
Lead Optimisation
IND Enabling
Clinical
Phase I
Phase II
Partner
Partner
Target
Undisclosed
Modality
mAb
Indication
Undisclosed
Pre-Clinical
Discovery
Hit Identification
Lead Optimisation
IND Enabling
Clinical
Phase I
Phase II
Partner
Partner
Target
EBV
Modality
TCR-T cell
Indication
Head & Neck
Pre-Clinical
Discovery
Hit Identification
Lead Optimisation
IND Enabling
Clinical
Phase I
Phase II
Partner
Partner
Target
CYT-AT1: EphA3
Modality
CAR-T
Indication
Solid Tumours/Hematological Tumours
Pre-Clinical
Discovery
Hit Identification
Lead Optimisation
IND Enabling
Clinical
Phase I
Phase II
Partner
Partner
Target
PDL1
Modality
Bicyclic Peptide
Indication
Solid Tumours
Pre-Clinical
Discovery
Hit Identification
Lead Optimisation
IND Enabling
Clinical
Phase I
Phase II
Partner
Partner
Target
SETDB1
Modality
Bicyclic Peptide
Indication
Solid Tumours
Pre-Clinical
Discovery
Hit Identification
Lead Optimisation
IND Enabling
Clinical
Phase I
Phase II
Partner
Partner
Target
G9a
Modality
Small Molecule
Indication
Solid Tumours
Pre-Clinical
Discovery
Hit Identification
Lead Optimisation
IND Enabling
Clinical
Phase I
Phase II
Target
Galectin-9
Modality
mAb
Indication
Solid Tumours
Pre-Clinical
Discovery
Hit Identification
Lead Optimisation
IND Enabling
Clinical
Phase I
Phase II
Partner
Partner
Target
PDL2
Modality
Protein
Indication
Solid Tumours
Pre-Clinical
Discovery
Hit Identification
Lead Optimisation
IND Enabling
Clinical
Phase I
Phase II
Target
HPV
Modality
TCR-T cell
Indication
Head & Neck/Cervical
Pre-Clinical
Discovery
Hit Identification
Lead Optimisation
IND Enabling
Clinical
Phase I
Phase II
Target
CYT-AT2: CD-19
Modality
CAR-T
Indication
Hematological Tumours
Pre-Clinical
Discovery
Hit Identification
Lead Optimisation
IND Enabling
Clinical
Phase I
Phase II
Partner
Partner
Target
CD226
Modality
Armoured CAR-T
Indication
Solid Tumours
Pre-Clinical
Discovery
Hit Identification
Lead Optimisation
IND Enabling
Clinical
Phase I
Phase II
Infectious Disease & Transplant
Completed
Started
Target
CMV
Modality
CTL Platform
Indication
Solid Organ Transplants
Pre-Clinical
Discovery
Hit Identification
Lead Optimisation
IND Enabling
Clinical
Phase I
Phase II
Target
JCPyV
Modality
CTL Platform
Indication
Multifocal Leukoencephalopathy
Pre-Clinical
Discovery
Hit Identification
Lead Optimisation
IND Enabling
Clinical
Phase I
Phase II
Target
BKPyV
Modality
CTL Platform
Indication
Undisclosed
Pre-Clinical
Discovery
Hit Identification
Lead Optimisation
IND Enabling
Clinical
Phase I
Phase II
Target
CMV
Modality
Vaccine
Indication
CMV Infection
Pre-Clinical
Discovery
Hit Identification
Lead Optimisation
IND Enabling
Clinical
Phase I
Phase II
Partner
Partner
Target
ACE2
Modality
Bicyclic Peptide
Indication
COPD
Pre-Clinical
Discovery
Hit Identification
Lead Optimisation
IND Enabling
Clinical
Phase I
Phase II
Target
gp350
Modality
mAb
Indication
EBV Associated PTLD
Pre-Clinical
Discovery
Hit Identification
Lead Optimisation
IND Enabling
Clinical
Phase I
Phase II
Target
Dengue Virus
Modality
Subviral RNA
Indication
Dengue Fever
Pre-Clinical
Discovery
Hit Identification
Lead Optimisation
IND Enabling
Clinical
Phase I
Phase II
Autoimmune, Neurology & Fibrosis
Completed
Started
Target
EBV
Modality
CTL Platform
Indication
Multiple Sclerosis
Pre-Clinical
Discovery
Hit Identification
Lead Optimisation
IND Enabling
Clinical
Phase I
Phase II
Partner
Partner
Target
Undisclosed
Modality
Protein
Indication
Undisclosed
Pre-Clinical
Discovery
Hit Identification
Lead Optimisation
IND Enabling
Clinical
Phase I
Phase II
Partner
Partner
Target
Galectin-9
Modality
mAb
Indication
Autoimmune
Pre-Clinical
Discovery
Hit Identification
Lead Optimisation
IND Enabling
Clinical
Phase I
Phase II
Partner
Partner
Target
mir-25
Modality
miRNA
Indication
Liver Fibrosis
Pre-Clinical
Discovery
Hit Identification
Lead Optimisation
IND Enabling
Clinical
Phase I
Phase II
Target
Undisclosed
Modality
mAb
Indication
Undisclosed
Pre-Clinical
Discovery
Hit Identification
Lead Optimisation
IND Enabling
Clinical
Phase I
Phase II
Partner
Partner
Target
Undisclosed
Modality
Small Molecule
Indication
Heart Failure/Sepsis
Pre-Clinical
Discovery
Hit Identification
Lead Optimisation
IND Enabling
Clinical
Phase I
Phase II
Diagnostics
Completed
Started
Biomarker
Platform
Diagnostic Method
Pre-Clinical
Discovery
Hit Identification
Lead Optimisation
IND Enabling
Clinical
Phase I
Phase II
Keep exploring
The future is here
View our available technologies
Cell manufacturing
Q-Gen is Australia's leading and most innovative cell manufacturer.
Why Partner With Us?
Together, we can translate innovative lab discoveries into successful commercial ventures, which make a significant impact on patient lives, drive medical innovations, and create a healthier future for people around the world.